Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

177.47USD
18 Apr 2019
Change (% chg)

$-5.00 (-2.74%)
Prev Close
$182.47
Open
$183.49
Day's High
$183.49
Day's Low
$176.90
Volume
2,501,992
Avg. Vol
1,289,470
52-wk High
$210.18
52-wk Low
$165.23

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 16.90 29.30 32.55
EPS (TTM): 11.00 -- --
ROI: 11.98 14.23 13.83
ROE: 26.43 15.46 15.25

Amgen sets $21,900 annual price for new Evenity bone drug

Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

15 Apr 2019

Amgen sets $21,900 annual price for new Evenity bone drug

April 15 Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

15 Apr 2019

Amgen's postmenopausal osteoporosis drug gets FDA greenlight

The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture.

09 Apr 2019

UPDATE 2-Amgen's postmenopausal osteoporosis drug gets FDA greenlight

April 9 The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture.

09 Apr 2019

Amgen's postmenopausal osteoporosis drug gets FDA approval

April 9 The U.S. Food and Drug Administration on Tuesday approved Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture, according to the regulator's website.

09 Apr 2019

Novartis, Amgen in dispute over migraine drug partnership

NEW YORK/LOS ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.

04 Apr 2019

UPDATE 3-Novartis, Amgen in dispute over migraine drug partnership

NEW YORK/LOS ANGELES, April 4 Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.

04 Apr 2019

BRIEF-Novartis Announced Today There Is A Legal Dispute With Amgen Regarding Collaboration Agreements In Field Of Migraine

* NOVARTIS ANNOUNCED TODAY THAT THERE IS A LEGAL DISPUTE WITH AMGEN REGARDING COLLABORATION AGREEMENTS IN FIELD OF MIGRAINE

04 Apr 2019

Novartis sues Amgen over migraine treatment Aimovig

NEW YORK, April 4 Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotech of trying to back out of the companies' agreements to develop and market Aimovig for the prevention of migraines.

04 Apr 2019

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

26 Feb 2019

Earnings vs. Estimates